OPKO Health Inc - Company Profile
Powered by 
All the sales intelligence you need on OPKO Health Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how OPKO Health Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with OPKO Health Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
OPKO Health Inc (OPKO) is a diversified healthcare company engaged in the discovery, development, and commercialization of serious disease medicines and diagnostic testing services. OPKO's major products include Rayaldee, a treatment for secondary hyperparathyroidism, and NGENLA, a human growth hormone therapy. The company also offers a range of diagnostic services through its subsidiary and collaborates with channel partners for the development and commercialization of its products. Its products and services are utilized by physicians, hospitals, and clinics. The company operates in the US, Europe, Japan, Canada, and Australia, with established, revenue-generating pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO is headquartered in Miami, Florida, the US.
Headquarters
United States of America
Address
4400 Biscayne Blvd., Miami, Florida, 33137
Website
www.opko.com
Telephone
1 305 5754100
No of Employees
2,275
Industry
Medical Equipment
Ticker Symbol & Exchange
OPK (NASD)
Revenue (2024)
$606.9M
-14.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-324%
(2024 vs 2023)
Market Cap*
$1.1B
Net Profit Margin (2024)
XYZ
-398.5%
(2024 vs 2023)
* As of and is in US$
OPKO Health Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Diagnostic Testing Equipment and Services | RAYALDEE |
| Somatrogon-Ghla: Human Growth Hormone Analog | NGENLA |
| Extended-Release (ER) Oral Formulation: Raising Serum Total 25D and Lowering Blood Levels of Intact Parathyroid Hormone | BioReference |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In October, ModeX Therapeutics Inc entered into a license and collaboration agreement with Regeneron Pharmaceuticals Inc to develop multispecific antibodies for several therapeutic indications. |
| 2025 | Asset Disposal | In September, the company sold BioReference Health's select assets to Labcorp Holdings Inc. |
| 2025 | Contracts/Agreements | In March, the company entered into a contract with Labcorp to sell BioReference Health's laboratory testing businesses. |
Competitor Comparison
| Key Parameters | OPKO Health Inc | Novartis AG | Siemens Healthineers AG | Labcorp Holdings Inc | Quest Diagnostics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | Germany | United States of America | United States of America |
| City | Miami | Basel | Forchheim | Burlington | Secaucus |
| State/Province | Florida | Basel-Stadt | Bayern | North Carolina | New Jersey |
| No. of Employees | 2,275 | 75,267 | 72,000 | 71,000 | 46,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Phillip Frost, MD, PhD | Chief Executive Officer; Chairman | Executive Board | 2007 | 89 |
| Elias A. Zerhouni | Vice Chairman; President | Executive Board | 2022 | 75 |
| Jane H. Hsiao, PhD | Chief Technical Officer; Vice Chairman | Executive Board | 2007 | 78 |
| Gary J. Nabel | Chief Innovation Officer; Director | Executive Board | 2022 | 72 |
| Adam Logal | Chief Financial Officer; Chief Accounting Officer; Senior Vice President; Treasurer | Senior Management | 2014 | 48 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer